Melanie Griffin Dr Claire Jennings Professor Gareth Veal
| Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated acute myeloid leukemia | 2021 |
|
Dr Britta Vormoor Professor Gareth Veal Melanie Griffin Professor Julie Irving Lynne Minto et al. | A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia | 2017 |
|
Dr David Jamieson Dr Nicola Sunter Sara Muro Dr Nicola Cresti Julieann Sludden et al. | Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide | 2017 |
|
Dr David Jamieson Melanie Griffin Julieann Sludden Dr Yvette Drew Dr Nicola Cresti et al. | A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours | 2016 |
|
Professor Andrew Pearson Dr Quentin Campbell Hewson Professor Alan Boddy Melanie Griffin
| A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study | 2015 |
|
Dr David Jamieson Dr Jo Lee Dr Nicola Cresti Melanie Griffin Julieann Sludden et al. | Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil | 2014 |
|
Dr David Jamieson Dr Nicola Cresti Julieann Sludden Melanie Griffin Nahed Hawsawi et al. | Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy | 2011 |
|
Melanie Griffin Professor Alan Boddy Professor Andrew Pearson
| Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia | 2010 |
|
Julieann Sludden Melanie Griffin Mike Cole Dr Mark Verrill Dr David Jamieson et al. | Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide | 2010 |
|
Professor Ruth Plummer Melanie Griffin Dr Sally Coulthard Julieann Sludden Professor Alan Calvert et al. | Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors | 2009 |
|
Professor Ruth Plummer Professor Alan Boddy Melanie Griffin Dr Mark Verrill
| A phase I and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies | 2008 |
|
Professor Alan Boddy Melanie Griffin Julie Errington Professor Gareth Veal
| Dosing of cancer patients with low or absent renal function | 2007 |
|
Dr Jo Lee Dr Mark Verrill Julieann Sludden Melanie Griffin Sharon Erb et al. | Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer | 2007 |
|
Professor Alan Boddy Julieann Sludden Melanie Griffin Professor Herbie Newell Professor Stephen O'Brien et al. | Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia | 2007 |
|
Professor Alan Boddy Professor Ruth Plummer Julieann Sludden Melanie Griffin Dr Mark Verrill et al. | A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules | 2005 |
|
Dr Ashraf Azzabi Dr Andrew Hughes Dr Paula Calvert Professor Ruth Plummer Melanie Griffin et al. | Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations | 2005 |
|
Professor Gareth Veal Julie Errington Julieann Sludden Melanie Griffin Annie Parry et al. | Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry | 2003 |
|
Julie Errington Professor Gareth Veal Julieann Sludden Melanie Griffin Professor Andrew Pearson et al. | Determination of the anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry | 2003 |
|
Dr Andrew Hughes Dr Paula Calvert Dr Ashraf Azzabi Professor Ruth Plummer Melanie Griffin et al. | Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma | 2002 |
|
Dr Andrew Simpson Dr Paula Calvert Julieann Sludden Professor Alan Boddy Melanie Griffin et al. | Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules | 2002 |
|
Professor Gareth Veal Melanie Griffin Annie Parry Dr Juliet Hale Professor Andrew Pearson et al. | A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin | 2001 |
|
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al. | Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer | 2001 |
|
Professor Alan Boddy Dr Mark Verrill Julieann Sludden Melanie Griffin Kevin Fishwick et al. | Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate | 2001 |
|
Dr Andrew Hughes Melanie Griffin Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al. | Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq(TM)) and paclitaxel | 2000 |
|
Melanie Griffin Professor Alan Boddy
| Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients | 2000 |
|
Melanie Griffin Professor Alan Boddy
| Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients | 2000 |
|
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al. | Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer | 2000 |
|
Dr Andrew Hughes Melanie Griffin Professor Alan Calvert Professor Herbie Newell Professor Alan Boddy et al. | Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days | 1999 |
|
Dr Andrew Hughes Melanie Griffin Professor Alan Calvert Andrew Johnston Professor Herbie Newell et al. | Pharmacokinetic interactions in a phase I study of nolatrexed (AG337, THYMITAQ TM) and paclitaxel in patients with advanced solid tumours | 1998 |
|
Professor Alan Boddy Melanie Griffin Dr Margaret Little Professor Andrew Pearson
| Pharmacokinetics and blood distribution in paediatric patients of SPI-77: Cisplatin encapsulated in Stealth® liposomes | 1998 |
|